Unicycive Therapeutics, Inc. ·
UNCY 8-K 2026-09-29
Unicycive Therapeutics, Inc. (UNCY) 8-K dated 2026-09-29 — accession 0001213900-26-104314.
Unicycive Therapeutics, Inc. (UNCY) is a biotechnology company listed on NASDAQ.
Unicycive Therapeutics, Inc. filed a 8-K on 2026-09-29. Accession 0001213900-26-104314.
This 8-K covers: Director/officer change (Item 5.02), Other events (Item 8.01), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.
Latest reported UNCY revenue for 2023-09-30 was $675.0K. Net income was -$4.3M. Revenue was up 0.0% from 2023-06-30 to 2023-09-30. UNCY currently screens at market cap $195.0M.
Not investment advice. The UNCY SEC hub lists recent forms. The stock page is the research view.